NO20090469L - Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav - Google Patents

Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav

Info

Publication number
NO20090469L
NO20090469L NO20090469A NO20090469A NO20090469L NO 20090469 L NO20090469 L NO 20090469L NO 20090469 A NO20090469 A NO 20090469A NO 20090469 A NO20090469 A NO 20090469A NO 20090469 L NO20090469 L NO 20090469L
Authority
NO
Norway
Prior art keywords
activity
increase
compounds
substituted piperidines
hdm2 protein
Prior art date
Application number
NO20090469A
Other languages
English (en)
Inventor
Stephane L Bogen
Ronald J Doll
Latha G Nair
Zhuyan Guo
Yaolin Wang
Jr Gerald W Shipps
Yao Ma
Brian R Lahue
Matthew E Voss
Yuan Tian
Corey O Strickland
Rumin Zhang
Mark A Mccoy
Weidong Pan
Elise M Siegel
Craig R Gibeau
Original Assignee
Albany Molecular Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albany Molecular Res Inc filed Critical Albany Molecular Res Inc
Publication of NO20090469L publication Critical patent/NO20090469L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives forbindelser som er inhibitorer av HDM2-protein, fremgangsmåter for å fremstille slike forbindelser, farmasøytiske preparater som innbefatter én eller flere slike forbindelser, anvendelse ved behandling, forebyggelse eller inhibering av én eller flere sykdommer forbundet med HDM2-protein eller P53, ved å anvende slike forbindelser eller farmasøytiske preparater.
NO20090469A 2006-06-30 2009-01-29 Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav NO20090469L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81775306P 2006-06-30 2006-06-30
PCT/US2007/014958 WO2008005268A1 (en) 2006-06-30 2007-06-27 Substituted piperidines that increase p53 activity and the uses thereof

Publications (1)

Publication Number Publication Date
NO20090469L true NO20090469L (no) 2009-03-27

Family

ID=38656615

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090469A NO20090469L (no) 2006-06-30 2009-01-29 Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav

Country Status (17)

Country Link
US (1) US7884107B2 (no)
EP (1) EP2035416A1 (no)
JP (1) JP2009542666A (no)
KR (1) KR20090042779A (no)
CN (1) CN101595107A (no)
AR (1) AR061726A1 (no)
AU (1) AU2007269836A1 (no)
BR (1) BRPI0713119A2 (no)
CA (1) CA2656398A1 (no)
CO (1) CO6150158A2 (no)
IL (1) IL196152A0 (no)
MX (1) MX2009000285A (no)
NO (1) NO20090469L (no)
PE (1) PE20081238A1 (no)
TW (1) TW200808781A (no)
WO (1) WO2008005268A1 (no)
ZA (1) ZA200900204B (no)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008157384A2 (en) 2007-06-15 2008-12-24 Microphage Incorporated Method of detection of microorganisms with enhanced bacteriophage amplification
US8546404B2 (en) * 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
JP2009528280A (ja) * 2006-02-16 2009-08-06 シェーリング コーポレイション Ｅｒｋインヒビターとしてのピロリジン誘導体
JP2009542664A (ja) * 2006-06-30 2009-12-03 シェーリング コーポレイション Ｐ５３活性を増大させる置換されたピペリジンの使用の方法
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US20080051375A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
DK2118123T3 (en) * 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
US8592377B2 (en) 2007-03-28 2013-11-26 President And Fellows Of Harvard College Stitched polypeptides
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
US8716483B2 (en) * 2008-02-21 2014-05-06 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
MX2010010165A (es) 2008-03-17 2010-11-25 Scripps Research Inst Procedimientos quimicos y geneticos combinados para generacion de celulas madre pluripotentes inducidas.
AR073578A1 (es) * 2008-09-15 2010-11-17 Priaxon Ag Pirrolidin-2-onas
MY160424A (en) * 2008-09-18 2017-03-15 Hoffmann La Roche Substituted pyrrolidine-2-carboxyamides.
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
WO2010077955A1 (en) 2008-12-17 2010-07-08 The Scripps Research Institute Generation and maintenance of stem cells
US7928233B2 (en) 2009-02-10 2011-04-19 Hoffmann-La Roche Inc. Spiroindolinone pyridine derivatives
US8217051B2 (en) 2009-02-17 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
PE20121172A1 (es) * 2009-10-14 2012-09-05 Merck Sharp & Dohme Piperidinas sustituidas con actividad en la hdm2
US8017607B2 (en) 2009-10-14 2011-09-13 Hoffmann-La Roche Inc. N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions
CA2777720C (en) 2009-10-16 2020-10-06 The Scripps Research Institute Induction of pluripotent cells
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8288431B2 (en) 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
CN102959076B (zh) 2010-03-31 2015-09-16 斯克里普斯研究所 重编程细胞
US8217044B2 (en) 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
JO2998B1 (ar) * 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
WO2011159684A2 (en) 2010-06-15 2011-12-22 Cellular Dynamics International, Inc. Generation of induced pluripotent stem cells from small volumes of peripheral blood
CA2806858C (en) 2010-08-04 2021-06-15 Cellular Dynamics International, Inc. Reprogramming immortalized b cells
ES2711526T3 (es) 2010-08-13 2019-05-06 Aileron Therapeutics Inc Macrociclos peptidomiméticos
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
WO2012080389A1 (en) * 2010-12-16 2012-06-21 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor
EP2655601A4 (en) 2010-12-22 2014-09-10 Fate Therapeutics Inc CELL CULTURAL PLATFORM FOR INDIVIDUAL CELL SIZING AND IMPROVED RESOLUTION OF IPSCS
US9415103B2 (en) 2011-06-14 2016-08-16 Yeda Research And Development Co. Ltd. Combination therapy to prevent DCIS formation and progression to breast cancer
JP2014520551A (ja) 2011-07-11 2014-08-25 セルラー ダイナミクス インターナショナル， インコーポレイテッド 細胞のリプログラミング方法およびゲノムの改変方法
US9376425B2 (en) 2011-09-27 2016-06-28 Amgen, Inc. Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
US8987274B2 (en) 2011-10-28 2015-03-24 Merck Sharp & Dohme Corp Macrocycles that increase p53 activity and the uses thereof
US9062071B2 (en) 2011-12-21 2015-06-23 Merck Sharp & Dohme Corp. Substituted piperidines as HDM2 inhibitors
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc TRIAZOL AND THIOETHER-COUPLED PEPTIDOMIMETIC MACROCYCLES
BR112014020103A2 (pt) * 2012-02-15 2018-10-09 Aileron Therapeutics, Inc. macrociclos peptidomiméticos
US20130245089A1 (en) * 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Method for administration
CN102690826B (zh) * 2012-04-19 2014-03-05 山西医科大学 一种特异性降低人Aurora-A基因表达的shRNA及其应用
WO2014024993A1 (ja) * 2012-08-09 2014-02-13 国立大学法人京都大学 ピぺラジン誘導体およびその用途
US9603844B2 (en) * 2012-10-22 2017-03-28 Georgetown University Compositions and methods for treating mammary tumors
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
WO2014134201A1 (en) 2013-02-28 2014-09-04 Amgen Inc. A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
MX374513B (es) 2013-03-14 2025-03-06 Amgen Inc Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer.
CN105358530A (zh) 2013-06-10 2016-02-24 美国安进公司 制备mdm2抑制剂的方法及其结晶形式
WO2014207688A1 (en) * 2013-06-26 2014-12-31 Universidade Do Porto Tryptophanol-derived oxazoloisoindolinones: small-molecule p53 activators
CA2941004A1 (en) 2014-03-04 2015-09-11 Peter Flynn Improved reprogramming methods and cell culture platforms
WO2016001376A1 (en) 2014-07-03 2016-01-07 Boehringer Ingelheim International Gmbh New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
RS59111B1 (sr) 2014-08-21 2019-09-30 Boehringer Ingelheim Int Nova jedinjenja spiro[3h-indol-3,2´-pirolidin]-2(1h)-ona i derivati kao mdm2-p53 inhibitori
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
AU2015320545C1 (en) 2014-09-24 2020-05-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
WO2016074580A1 (zh) * 2014-11-14 2016-05-19 中国科学院上海生命科学研究院 一种提高cd4阳性t淋巴细胞存活率和活性的试剂及其应用
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
EP3865139B1 (en) 2015-02-18 2023-05-03 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
WO2016170541A1 (en) 2015-04-21 2016-10-27 Enlivex Therapeutics Ltd. Therapeutic pooled blood apoptotic cell preparations and uses thereof
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
WO2017044633A1 (en) 2015-09-10 2017-03-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of mcl-1
KR20240158360A (ko) 2015-10-09 2024-11-04 베링거 인겔하임 인터내셔날 게엠베하 Mdm2-p53 억제제로서의 스피로[3h-인돌-3,2'-피롤리딘]-2(1h)-온 화합물 및 유도체
CN117737124A (zh) 2015-10-16 2024-03-22 菲特治疗公司 用于诱导和维护基态多能性的平台
SG11201803419PA (en) 2015-10-30 2018-05-30 The Regents Of The Universtiy Of California Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
CN109069539A (zh) 2016-02-18 2018-12-21 恩立夫克治疗有限责任公司 用于癌症治疗的联合免疫疗法和细胞因子控制疗法
UA124972C2 (uk) 2016-07-29 2021-12-22 Янссен Фармацевтика Нв Способи лікування раку передміхурової залози
RU2019110821A (ru) 2016-09-20 2020-10-22 Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед Антагонисты trpv4
JP2019532054A (ja) 2016-09-20 2019-11-07 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｔｒｐｖ４拮抗薬
TW201825458A (zh) 2016-09-20 2018-07-16 英商葛蘭素史克智慧財產（第二）有限公司 Ｔｒｐｖ４拮抗劑
WO2018185135A1 (en) 2017-04-05 2018-10-11 Boehringer Ingelheim International Gmbh Anticancer combination therapy
WO2019134070A1 (en) * 2018-01-02 2019-07-11 Rui Jin Hospital, Shanghai Jiao Tong University School Of Medicine Panda as novel therapeutic
CN108864113B (zh) * 2018-08-03 2021-08-13 南方科技大学 一种mdm2-hdac双靶点抑制剂、药物组合物及其制备和用途
CN109293630A (zh) * 2018-11-15 2019-02-01 山东大学 含取代吡唑类化合物及其制备方法与应用
CN110643557B (zh) * 2019-04-23 2021-12-31 天津科技大学 一种基因工程菌的构建及其在高效催化5α-雄烯二酮生产中的应用
AU2020292965A1 (en) * 2019-06-10 2022-01-27 Adc Therapeutics Sa Combination therapy comprising an anti-CD19 antibody drug conjugate and a PI3K inhibitor or a secondary agent
AU2020346814A1 (en) * 2019-09-13 2022-02-17 Dana-Farber Cancer Institute, Inc. KDM inhibitors and uses thereof
CN113633642A (zh) * 2021-08-26 2021-11-12 山东第一医科大学附属青岛眼科医院(山东省眼科研究所、青岛眼科医院) Abt-263在制备抑制角膜移植免疫排斥反应的药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09249566A (ja) 1996-03-19 1997-09-22 Takeda Chem Ind Ltd ピペリジン化合物含有ケモカイン受容体拮抗剤
WO1998016527A1 (en) * 1996-10-15 1998-04-23 Fujisawa Pharmaceutical Co., Ltd. Benzoxepine derivatives which promote release of growth hormone
JP2000514838A (ja) * 1997-05-14 2000-11-07 藤沢薬品工業株式会社 成長ホルモンの放出を促進するピペリジノ誘導体
EP0947494A1 (en) 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Derivatives of phenoxy acetic acid and phenoxymethyltetrazole having antitumor activity
JP4142253B2 (ja) * 1998-05-11 2008-09-03 ノボ ノルディスク アクティーゼルスカブ 成長ホルモン放出特性を有する化合物
GB9819860D0 (en) 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
AR035312A1 (es) * 1999-01-27 2004-05-12 Wyeth Corp Compuestos de acido hidroxamico que contienen alquinilo como inhibidores de metaloproteinasa de matriz/tace, composicion farmaceutica que los comprenden y el uso de los mismos para la manufactura de un medicamento
UA73530C2 (uk) * 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
ES2291323T3 (es) * 2000-06-15 2008-03-01 Schering Corporation Antagonistas de receptores de trombina.
US6403584B1 (en) 2000-06-22 2002-06-11 Merck & Co., Inc. Substituted nipecotyl derivatives as inhibitors of cell adhesion
US20020099035A1 (en) * 2001-01-24 2002-07-25 Sandanayaka Vincent P. Method for preparing alpha-sulfonyl hydroxamic acid derivatives
PL370823A1 (en) 2001-12-18 2005-05-30 F.Hoffmann-La Roche Ag Cis-2,4,5- triphenyl-imidazolines and their use in the treatment of tumors
CN1182113C (zh) * 2002-07-19 2004-12-29 中国科学院上海有机化学研究所 2，5－cis－二取代的吡咯烷衍生物、合成方法及其用途
US6916833B2 (en) 2003-03-13 2005-07-12 Hoffmann-La Roche Inc. Substituted piperidines
US7632920B2 (en) * 2003-04-10 2009-12-15 Schering Corporation Soluble, stable form of HDM2, crystalline forms thereof and methods of use thereof
US7132421B2 (en) 2003-06-17 2006-11-07 Hoffmann-La Roche Inc. CIS-imidazoles
US7425638B2 (en) 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
JP4814228B2 (ja) 2004-05-18 2011-11-16 エフ．ホフマン−ラ ロシュ アーゲー 新規ｃｉｓ−イミダゾリン
KR101417136B1 (ko) 2005-12-13 2014-08-07 머크 샤프 앤드 돔 코포레이션 Ｅｒｋ 억제제인 폴리사이클릭 인다졸 유도체 및 이를 포함하는 약제학적 조성물

Also Published As

Publication number Publication date
WO2008005268A1 (en) 2008-01-10
TW200808781A (en) 2008-02-16
AU2007269836A1 (en) 2008-01-10
EP2035416A1 (en) 2009-03-18
US20080004287A1 (en) 2008-01-03
AR061726A1 (es) 2008-09-17
US7884107B2 (en) 2011-02-08
CO6150158A2 (es) 2010-04-20
PE20081238A1 (es) 2008-09-04
CA2656398A1 (en) 2008-01-10
CN101595107A (zh) 2009-12-02
JP2009542666A (ja) 2009-12-03
MX2009000285A (es) 2009-06-08
ZA200900204B (en) 2010-01-27
KR20090042779A (ko) 2009-04-30
IL196152A0 (en) 2009-09-22
BRPI0713119A2 (pt) 2012-04-17

Similar Documents

Publication Publication Date Title
NO20090469L (no) Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav
NO20090628L (no) Pyridizinon derivativater
NO20092658L (no) New compounds
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
NO20092569L (no) Inhibitorer av Akt-aktivitet
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
LTC1934174I2 (lt) Azetinidai kaip MEK inhibitoriai, skirti proliferacinių ligų gydymui
NO20084652L (no) Deazapuriner anvendelige som inhibitorer av januskinaser
NO20083501L (no) Azaindoler som er anvendelige som inhibitorer for Janus-kinaser
NO20091605L (no) Pyridinonforbindelser
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
UA109417C2 (uk) ЗАМІЩЕНІ ПІПЕРИДИНИ, ЯКІ ПІДВИЩУЮТЬ АКТИВНІСТЬ p53, І ЇХ ЗАСТОСУВАННЯ
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
NO20084256L (no) DPP IV inhibitorformuleringer
EA200870019A1 (ru) Лактамовые соединения и способы их применения
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
DK1636236T3 (da) Pyrazolo-quinazolin-derivater, en fremgangsmåde til fremstilling deraf, og deres anvendelse som kinase-inhibitorer
EA200802390A1 (ru) Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их
TW200833693A (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
NO20080785L (no) Behandling av kreft
WO2008131000A3 (en) 7-substituted indole mcl-1 inhibitors
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
BRPI0622054B8 (pt) composto e composição farmacêutica
NO20081838L (no) 5-lipoksygenaseaktiverende protein-(FLAP)-inhibitorer
NO20083572L (no) Tiazolforbindelser som proteinkinase-B (PKB)-inhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application